

(d) In case of an initial request for certification, each other ingredient used in making the batch: One package of each containing approximately 5 grams.

(b) *Tests and methods of assay*—(1) *Potency*—(i) *Neomycin content*. Proceed as directed in § 444.42a(b)(1) except prepare the sample as follows: Remove an accurately measured representative portion of the sample with a suitable syringe, place into an appropriate volumetric flask to yield a convenient stock solution. Dilute to volume with 0.1M potassium phosphate buffer, pH 8.0. Further dilute with 0.1 M potassium phosphate buffer, pH 8.0, to the proper prescribed reference concentration. Its content of neomycin is satisfactory if it is not less than 90 percent and not more than 130 percent of the number of milligrams of neomycin that it is represented to contain.

(ii) *Polymyxin content*. Remove an accurately measured representative portion with a suitable syringe, dilute to a convenient concentration with 10 percent potassium phosphate buffer, pH 6.0. Further dilute to a concentration of 10 units of polymyxin per milliliter with 10 percent potassium phosphate buffer, pH 6.0, and proceed as directed in § 448.30a(b)(1) of this chapter, except add to each concentration of the polymyxin standard curve a quantity of neomycin to yield the same concentration of neomycin as that present when the sample is diluted to contain 10 units of polymyxin per milliliter. Its content of polymyxin is satisfactory if it is not less than 90 percent and not more than 130 percent of the number of units of polymyxin that it is represented to contain.

(2) *Sterility*. Proceed as directed in § 436.20 of this chapter, using the method described in paragraph (e)(1) of that section, except if the steroid prevents solubilization, use 0.25 milliliter of sample in lieu of 1 milliliter and proceed as directed in paragraph (e)(2) of that section.

(3) *pH*. Proceed as directed in § 440.80a(b)(5)(ii) of this chapter, using the undiluted sample.

[39 FR 19045, May 30, 1974, as amended at 42 FR 37975, July 26, 1977; 47 FR 23441, May 28, 1982; 49 FR 5097, Feb. 10, 1984; 49 FR 34351, Aug. 30, 1984; 50 FR 19919, May 13, 1985; 59 FR 8399, Feb. 22, 1994]

§ 444.342e Neomycin sulfate ointment; neomycin sulfate- _____ ointment (the blank being filled in with the established name(s) of certain other active ingredient(s)).

The requirements for certification and the tests and methods of assay for neomycin sulfate ointment and for neomycin sulfate- _____ ointment are described in § 444.542a.

§ 444.342f Neomycin sulfate-gramicidin topical ointment; neomycin sulfate-gramicidin-triamcinolone acetonide ointment; neomycin sulfate-gramicidin-fludrocortisone acetate ointment.

The requirements for certification and the tests and methods of assay for neomycin sulfate-gramicidin topical ointment; neomycin sulfate-gramicidin-triamcinolone acetonide ointment; neomycin sulfate-gramicidin-fludrocortisone acetate ointment are described in § 444.542f.

§ 444.342g Neomycin sulfate-hydrocortisone acetate ophthalmic suspension; neomycin sulfate-prednisolone acetate ophthalmic suspension.

(a) *Requirements for certification*—(1) *Standards of identity, strength, quality, and purity*. Neomycin sulfate-hydrocortisone acetate ophthalmic suspension is an aqueous suspension containing in each milliliter 3.5 milligrams of neomycin and 5 milligrams or 15 milligrams of hydrocortisone acetate. Neomycin sulfate-prednisolone acetate ophthalmic suspension is an aqueous suspension containing in each milliliter 3.5 milligrams of neomycin and 2.5 milligrams of prednisolone acetate. The vehicle contains one or more suitable and harmless buffers, preservatives, and dispersants. It is sterile. Its